Earnings results for Kazia Therapeutics (NASDAQ:KZIA)
Kazia Therapeutics Limited is estimated to report earnings on 08/26/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date.
Analyst Opinion on Kazia Therapeutics (NASDAQ:KZIA)
1 Wall Street analysts have issued ratings and price targets for Kazia Therapeutics in the last 12 months. Their average twelve-month price target is $17.00, predicting that the stock has a possible upside of 76.17%. The high price target for KZIA is $17.00 and the low price target for KZIA is $17.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”
Kazia Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $17.00, Kazia Therapeutics has a forecasted upside of 76.2% from its current price of $9.65. Kazia Therapeutics has received no research coverage in the past 90 days.
Dividend Strength: Kazia Therapeutics (NASDAQ:KZIA)
Kazia Therapeutics does not currently pay a dividend. Kazia Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Kazia Therapeutics (NASDAQ:KZIA)
In the past three months, Kazia Therapeutics insiders have not sold or bought any company stock. Only 1.00% of the stock of Kazia Therapeutics is held by insiders. Only 3.59% of the stock of Kazia Therapeutics is held by institutions.
Earnings and Valuation of Kazia Therapeutics (NASDAQ:KZIA
Earnings for Kazia Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.85) per share. The P/E ratio of Kazia Therapeutics is -7.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Kazia Therapeutics is -7.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Kazia Therapeutics has a P/B Ratio of 9.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here